trending Market Intelligence /marketintelligence/en/news-insights/trending/a56hoqgcxabcb7rynwsaug2 content esgSubNav
In This List

CymaBay closes common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


CymaBay closes common stock offering

CymaBay Therapeutics Inc. closed an offering of 13,340,000 shares priced $10.80 each.

Stocks issued include the 1,740,000 that underwriters acquired via their overallotment option.

Leerink Partners LLC and Evercore ISI were the joint book-running managers for the offering which will help fund the ongoing development of the Newark, Calif.-based clinical-stage biopharmaceutical company's seladelpar.

Seladelpar is in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis and nonalcoholic steatohepatitis.

Oppenheimer & Co. Inc. acted as lead manager and H.C. Wainwright & Co. LLC and Roth Capital Partners acted as co-managers for the offering.